Mucpharm
↗Kogarah, Sydney, New South Wales 2217, Australia
Mucpharm is a specialized Australian biotech company established in 2017 by Professor David Morris and the Herszberg Family, focused on developing innovative treatments for mucin-containing and secreting cancers and other diseases involving glycoproteins. The company's lead asset, BromAc®, is a patented combination of bromelain and acetylcysteine that synergistically dissolves tumor-produced mucin, enhancing the effectiveness of chemotherapy and other treatments. Mucpharm is currently advancing BromAc through Phase 2 clinical trials for pseudomyxoma peritonei (PMP), a rare orphan disease characterized by progressive accumulation of jelly-like material within the abdomen. The company is exploring multiple therapeutic applications including oncology, respiratory diseases, and peritoneal malignancies.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Oncology biotech, rare disease therapeutics
SIZE & FINANCIALS
Employees:11-50
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Early-stage / clinical development
Total Raised:Not publicly disclosed
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Enzyme combination therapy, Small molecule (bromelain + acetylcysteine)
Active Trials:2
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Niche player with proprietary technology
Competitors:Larger oncology companies developing peritoneal cancer treatments, Other rare disease therapeutic companies
LEADERSHIP
Key Executives:
Professor David L Morris - Chairman and Co-Founder
Mark Lawrence - CEO and Co-Founder
Myer Herszberg - Director
Dr Jon Fairweather - Head of CMC Clinical & Regulatory
Steven Davis - Head of CMC Clinical & Regulatory
Scientific Founders:Professor David L Morris (Surgical Oncology, drug development expertise)
Board Members:Professor David L Morris (Chairman), Myer Herszberg, Mark Lawrence
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Mucpharm and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Mucpharm. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.